Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Icosavax revenue
Icosavax's revenue is $582,000.
What is Icosavax's revenue?
- Icosavax's revenue growth from 2020 to 2022 is -63.99%.
- Icosavax has 34 employees, and the revenue per employee ratio is $17,117.
- Icosavax's peak quarterly revenue was $2.1M in 2021(q4).
- Icosavax peak revenue was $7.8M in 2021.
- Icosavax annual revenue for 2021 was 7.8M, 382.8% growth from 2020.
- Icosavax annual revenue for 2022 was 582.0K, -92.54% growth from 2021.
On this page
Zippi applies for you, and finds you a job.
Icosavax historical revenue
Icosavax's peak revenue was $7.8M in 2021. The peak quarterly revenue was $2.1M in 2021(q4).
Icosavax's revenue increased from $1.6m in 2020 to $582.0K currently. That's a -63.99% change in annual revenue.
Icosavax annual revenue
Icosavax annual revenue over time
| Fiscal year / year | Icosavax revenue |
|---|---|
| 2020 | $1.6M |
| 2021 | $7.8M |
| 2022 | $582,000 |
Icosavax jobs nearby
Do you work at Icosavax?
Is Icosavax transparent about its revenue structure?
Icosavax financing
Icosavax received early financing of $51.0M on 2019-10-03.
| Series | Round size | Date |
|---|---|---|
| Series A | $51M | 10/2019 |
| Grant | $10M | 10/2020 |
| Series B | $100M | 04/2021 |
Icosavax investors
| Investors | Security type |
|---|---|
| Adams Street Partners | Series A |
| Sanofi Ventures | Series A |
| Qiming Venture Partners USA | Series A |
| SANOFI | Series A |
| NanoDimension | Series A |
| Bill & Melinda Gates Foundation | Grant |
| Viking Global Investors | Series B |
| Adams Street Partners | Series B |
| Cormorant Asset Management | Series B |
| Perceptive Advisors | Series B |
| Omega Funds | Series B |
| Sanofi Ventures | Series B |
| Janus Henderson Investors | Series B |
| Qiming Venture Partners USA | Series B |
| RA Capital Management | Series B |
| NanoDimension | Series B |
| Open Philanthropy Project | Series B |
| Surveyor Capital | Series B |
Icosavax competitors
Icosavax's top competitor, Novavax, earned an annual revenue of $682.2M.
Icosavax's smallest competitor is Aptimmune Biologics with revenue of $460.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Novavax | - | $682.2M | 791 | - |
| VBI Vaccines | - | $1.0M | 22 | - |
| Vaxart | - | $28.7M | 110 | - |
| Soligenix | - | $2.4M | 14 | - |
| Genocea | - | - | 59 | - |
| Aptimmune Biologics | - | $460,000 | 9 | - |
| SIGA Technologies | - | $115.5M | 43 | - |
| Meissa Vaccines | - | $530,000 | 19 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Icosavax, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Icosavax. The employee data is based on information from people who have self-reported their past or current employments at Icosavax. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Icosavax. The data presented on this page does not represent the view of Icosavax and its employees or that of Zippia.
Icosavax may also be known as or be related to ICOSAVAX, INC., Icosavax, Icosavax Inc and Icosavax, Inc.